The first strategy was to define if enhancing ARF1 expression could increase ERK1/2 activation in normal prostate cells and the second strategy was to determine if reducing ARF1 expression could decrease ERK1/2 activation in prostate cancer cells. Here, ARF1 is linked to Familial prostate cancer.